Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer

Shibata,Ryosuke; Nimura,Satoshi; Hashimoto,Tatsuya; Miyake,Toru; Takeno,Shinsuke; Hoshino,Seiichiro; Nabeshima,Kazuki; Yamashita,Yuichi

doi:10.3892/mco.2014.329

Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer

Authors:
- Ryosuke Shibata
- Satoshi Nimura
- Tatsuya Hashimoto
- Toru Miyake
- Shinsuke Takeno
- Seiichiro Hoshino
- Kazuki Nabeshima
- Yuichi Yamashita
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka 814‑0180, Japan, Department of Pathology, Fukuoka University Faculty of Medicine, Fukuoka 814‑0180, Japan
Published online on: June 27, 2014 https://doi.org/10.3892/mco.2014.329
Pages: 751-755

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human epidermal growth factor receptor 2 (HER2) status has been evaluated at the primary site of gastric cancer when planning trastuzumab therapy against recurrent or metastatic lesions, since tissue sampling is uncommon in recurrent or metastatic lesions. This study retrospectively investigated the concordance of HER2 expression between primary and metastatic/recurrent lesions in order to confirm sensitivity to trastuzumab. The subjects comprised 37 patients with gastric adenocarcinoma who underwent tissue biopsy or surgical resection of the primary sites and 49 paired synchronous or metachronous metastatic sites (excluding lymph nodes) at the Fukuoka University Hospital between January, 1998 and September, 2012. All the samples were evaluated for HER2 status at the invasive front by immunohistochemistry (IHC). The HER2 positivity rate of the primary sites was ~16% and the concordance ratio of the IHC results between primary and paired metastatic sites was ~97%. no discordant cases regarding HER2 status were found among metachronous interventions for metastatic lesions. Only one patient exhibited conversion from a HER2‑negative status in all the portions of the primary site to a positive status in a metastatic site. In conclusion, a high concordance ratio for HER2 status was observed between primary and paired metastatic lesions. Thus, employing trastuzumab therapy against metastatic or recurrent gastric cancer based on the HER2 status of the primary lesion appears to be an acceptable approach.

View Figures

View References

1	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar
2	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
3	Otsuji E, Yamaguchi T, Sawai K, et al: Recent advances in surgical treatment have improved the survival of patients with gastric carcinoma. Cancer. 82:1233–1237. 1998. View Article : Google Scholar : PubMed/NCBI
4	Horner MJ, Ries LAG, Krapcho M, et al: SEER Cancer Statistics Review, 1975–2006. http://seer.cancer.gov/archive/csr/1975_2006/results_merged/sect_24_stomach.pdf. Accessed April 12, 2009
5	Cunningham SC, Kamangar F, Kim MP, et al: Survival after gastric adenocarcinoma serection: eighteen-year experience at a single institution. J Gastrointest Surg. 9:718–725. 2005.PubMed/NCBI
6	Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar
7	Cardoso F, Di Leo A, Larsimont D, et al: Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol. 12:615–620. 2001. View Article : Google Scholar : PubMed/NCBI
8	Simon R, Nocito A, Huebscher T, et al: Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst. 93:1141–1146. 2001. View Article : Google Scholar : PubMed/NCBI
9	Chang HJ, Han SW, Oh DY, et al: Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn J Clin Oncol. 41:593–599. 2011. View Article : Google Scholar
10	Chan A, Morey A, Brown B, et al: A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease. BMC Cancer. 12:5552012. View Article : Google Scholar : PubMed/NCBI
11	Marx AH, Tharun L, Muth J, et al: HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 40:769–777. 2009. View Article : Google Scholar : PubMed/NCBI
12	Fassan M, Ludwig K, Pizzi M, et al: Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum Pathol. 43:1206–1212. 2012. View Article : Google Scholar : PubMed/NCBI
13	Tafe LJ, Janjigian YY, Zaidinski M, et al: Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med. 135:1460–1465. 2011. View Article : Google Scholar
14	Hofmann M, Stoss O, Shi D, et al: Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 52:797–805. 2008. View Article : Google Scholar : PubMed/NCBI
15	Kunz PL, Mojtahed A, Fisher GA, et al: HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 20:13–24. 2012. View Article : Google Scholar
16	Kataoka Y, Okabe H, Yoshizawa A, et al: HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 16:84–93. 2013. View Article : Google Scholar : PubMed/NCBI
17	Kim MA, Lee HJ, Yang HK, et al: Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology. 59:822–831. 2011. View Article : Google Scholar
18	Lee S, de Boer WB, Fermoyle S, et al: Human epidermal growth factor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology. 59:832–840. 2011. View Article : Google Scholar : PubMed/NCBI
19	Takehara T, Kunitomo K, Kono K, et al: Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 98:833–837. 2002. View Article : Google Scholar
20	Yano T, Doi T, Ohtsu A, et al: Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 15:65–71. 2006.
21	Wolff AC, Hammond ME, Schwartz JN, et al; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 25:118–145. 2007. View Article : Google Scholar
22	Bozzetti C, Negri FV, Lagrasta CA, et al: Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 104:1372–1376. 2011. View Article : Google Scholar : PubMed/NCBI
23	Nakamura R, Yamamoto N, Onai Y, et al: Importance of confirming HER2 overexpression of recurrence lesion in breast cancer patients. Breast Cancer. 20:336–341. 2013. View Article : Google Scholar : PubMed/NCBI
24	Kim KC, Koh YW, Chang HM, et al: Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 18:2833–2840. 2011. View Article : Google Scholar
25	Fusco N, Rocco EG, Del Conte C, et al: HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod Pathol. 26:816–824. 2013. View Article : Google Scholar : PubMed/NCBI
26	Kochi M, Fujii M, Masuda S, et al: Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes. Diagn Pathol. 8:1912013. View Article : Google Scholar : PubMed/NCBI